Alexion Pharmaceuticals, Inc. is known for developing and manufacturing specialized drugs, primarily focusing on treatments for rare diseases. The company's portfolio includes medications like Kanuma, Soliris, and Strensiq.
Overview of Alexion Pharmaceuticals' Drugs
Alexion's drug offerings target specific medical conditions, often involving enzyme deficiencies or immune system dysregulation. Here's a breakdown of the drugs manufactured by Alexion:
| Brand Name | Generic Name | Drug Class |
|---|---|---|
| Kanuma | sebelipase alfa | Lysosomal Enzymes |
| Soliris | eculizumab | Selective Immunosuppressants |
| Strensiq | asfotase alfa | Miscellaneous Metabolic Agents |
For more detailed information on Alexion's products and company profile, you can visit the Alexion Pharmaceuticals, Inc. page on Drugs.com.
Kanuma (sebelipase alfa)
Kanuma is a medication classified under lysosomal enzymes. It is specifically designed to provide an enzyme replacement therapy for patients with Lysosomal Acid Lipase (LAL) Deficiency, a rare genetic disorder that affects the body's ability to break down certain fats.
Soliris (eculizumab)
Soliris falls under the category of selective immunosuppressants. This drug is used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It works by inhibiting a specific part of the immune system to prevent the destruction of red blood cells or damage to tissues.
Strensiq (asfotase alfa)
Strensiq is categorized as a miscellaneous metabolic agent. It is indicated for the treatment of hypophosphatasia (HPP), a rare metabolic bone disorder characterized by defective bone mineralization. Strensiq works by replacing the missing enzyme that is crucial for normal bone and tooth development.
